TIDMPRTC
RNS Number : 6953A
PureTech Health PLC
01 October 2020
1 October 2020
PureTech Health plc
PureTech Appoints Kiran Mazumdar-Shaw, Founder and Chairperson
of a Leading Global Biopharmaceutical Company, to Board of
Directors
PureTech Health plc (LSE: PRTC) ("PureTech"), a clinical stage
biotherapeutics company dedicated to discovering, developing and
commercialising highly differentiated medicines for devastating
diseases, today announced the appointment of biotech entrepreneur
Kiran Mazumdar-Shaw to its board of directors. Ms Shaw is an
industry trailblazer who has spent her career surpassing societal
expectations as the founder and chairperson of India's largest and
a leading global biopharmaceutical company, Biocon Limited. Driven
by a commitment to provide access to life-saving medicines
worldwide, Ms Shaw brings extensive experience in biotherapeutics,
strategic leadership, financial and business development and a
dedication to improving patients' lives to PureTech's board of
industry leaders.
"Kiran is a tremendously successful entrepreneur in healthcare
and widely recognised as one of the most powerful and influential
women in business. She also has a keen interest in improving the
health of people around the world," said Christopher Viehbacher,
chairman of PureTech's board of directors. "Kiran brings a wealth
of experience and knowledge to PureTech's board as we enter this
next exciting chapter of growth."
Ms Shaw is a pioneer of the biotechnology industry in India and
a noted philanthropist who has devoted herself to building a
sustainable model for delivering top-quality diabetes and cancer
care at affordable prices. Since she founded Biocon, she has guided
its growth from a leading bioenzymes company of India to a fully
integrated and globally recognised multibillion-dollar biopharma
company with extensive research efforts in oncology, diabetes and
autoimmune disease. In addition to her leadership of Biocon, Ms
Shaw chairs the Indian State of Karnataka's Vision Group on
Biotechnology and is on the Advisory Council of the Indian
government's Department of Biotechnology. She serves on the Board
of Trustees at Massachusetts Institute of Technology (MIT) and the
Keck Graduate Institute (KGI). Ms Shaw is an independent director
on the board of Infosys and Narayana Health. She is also an elected
international member of the prestigious US National Academy of
Engineering (NAE).
Ms Shaw founded the Mazumdar Shaw Cancer Centre in Bangalore,
which focuses on delivering affordable care. She is also the
driving force behind the Biocon Foundation, which runs primary
healthcare clinics to reach India's rural poor. Ms Shaw has
received multiple industry accolades including being named among
Forbes' World's 100 Most Powerful Women and World's Self-Made Women
Billionaires, Fortune's Top 25 Most Powerful Women in Asia-Pacific,
TIME Magazine's 100 Most Influential People in the World,
FierceBiotech's World's 25 Most Influential People in Biopharma,
Scientific American's The Worldview 100 List of the most
influential visionaries, Foreign Policy's 100 Leading Global
Thinkers and the Medicine Maker Power List, a ranking of the 100
most influential people in medicine from across the globe. Ms Shaw
was also declared the EY World Entrepreneur of 2020. She is a
recipient of several national honours including the Padma Shri
(1989) and Padma Bhushan (2005), two of India's most prestigious
civilian awards, the Knight of the Legion d'Honneur, France (2016)
and The Order of Australia (2020). Ms Shaw has a graduate degree in
zoology from Bangalore University and has earned a master's degree
in malting and brewing from Ballarat College, Melbourne University.
She has received honorary doctorates from several institutions
globally.
"I am thrilled to join the luminaries on PureTech's board at a
time when the company is poised for rapid growth building on the
many successes of recent years," Ms Shaw said. "With a unique and
extremely productive approach towards the development of new
medicines, the PureTech team has developed an impressive track
record of pioneering new therapies, all of which could be
transformational across a number of fields. With exciting
programmes within its Wholly Owned Pipeline, PureTech has the
potential to be truly disruptive in addressing serious diseases
where there is significant need."
"Kiran is an entrepreneur and visionary who is credited with the
conception, development and success of a highly respected and
important biopharma enterprise," said Daphne Zohar, founder and
chief executive officer of PureTech. "Her proven track record of
entrepreneurial ingenuity and integrity along with her demonstrated
business leadership position her as an excellent addition to
PureTech's board of industry leaders. We are excited to work with
her as we continue on our growth trajectory."
On joining the board, Ms Shaw will become a member of the
board's Remuneration and Nomination Committees.
Additional Information
Ms Shaw is independent for the purposes of the UK Corporate
Governance Code.
Ms Shaw has served as an independent director of Infosys (NYSE:
INFY) since 2014.
Except as set out in this announcement, no disclosure
obligations arise under paragraphs (1) to (6) of LR 9.6.13 of the
Financial Conduct Authority's Listing Rules in connection with Ms
Shaw's appointment.
About PureTech Health
PureTech is a clinical stage biotherapeutics company dedicated
to discovering, developing and commercialising highly
differentiated medicines for devastating diseases, including
intractable cancers, lymphatic and gastrointestinal diseases,
central nervous system disorders and inflammatory and immunological
diseases, among others. The Company has created a broad and deep
pipeline through the expertise of its experienced research and
development team and its extensive network of scientists,
clinicians and industry leaders. This pipeline, which is being
advanced both internally and through PureTech's Founded Entities,
is comprised of 24 products and product candidates, including two
that have received US Food and Drug Administration (FDA ) clearance
and European marketing authorisation. All of the underlying
programmes and platforms that resulted in this pipeline of product
candidates were initially identified or discovered and then
advanced by the PureTech team through key validation points based
on the Company's unique insights into the biology of the brain,
immune and gut, or BIG, systems and the interface between those
systems, referred to as the BIG Axis.
For more information, visit www.puretechhealth.com or connect
with us on Twitter @puretechh.
Forward Looking Statement
This press release contains statements that are or may be
forward-looking statements, including statements that relate to the
company's future prospects, growth, developments, and strategies.
The forward looking statements are based on current expectations
and are subject to known and unknown risks and uncertainties that
could cause actual results, performance and achievements to differ
materially from current expectations, including, but not limited to
our expectations regarding the addition of Ms Shaw to our board of
directors and those risks and uncertainties described in the risk
factors included in the regulatory filings for PureTech Health plc.
These forward-looking statements are based on assumptions regarding
the present and future business strategies of the company and the
environment in which it will operate in the future. Each
forward-looking statement speaks only as at the date of this press
release. Except as required by law and regulatory requirements,
neither the company nor any other party intends to update or revise
these forward-looking statements, whether as a result of new
information, future events or otherwise.
This announcement contains inside information for the purposes
of Article 7 of Regulation (EU) 596/2014.
Contact:
Investors EU media US media
Allison Mead Talbot Ben Atwell, Rob Winder Stephanie Simon
+1 617 651 3156 +44 (0) 20 3727 1000 +1 617 581 9333
amt@puretechhealth.com ben.atwell@FTIconsulting.com stephanie@tenbridgecommunications.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BOAEAFNEDSNEEAA
(END) Dow Jones Newswires
October 01, 2020 02:05 ET (06:05 GMT)
Puretech Health (LSE:PRTC)
Historical Stock Chart
From Apr 2024 to May 2024
Puretech Health (LSE:PRTC)
Historical Stock Chart
From May 2023 to May 2024